Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats

Asada, Yohei; Takayanagi, Takeshi; Kawakami, Tsukasa; Tomatsu, Eisuke; Masuda, Atsushi; Yoshino, Yasumasa; Sekiguchi-Ueda, Sahoko; Shibata, Megumi; Ide, Tomihiko; Niimi, Hajime; Yaoita, Eishin; Seino, Yusuke; Sugimura, Yoshihisa; Suzuki, Atsushi

doi:https://doi.org/10.1155/2019/4194853

International Journal of Endocrinology

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusion Data Availability Conflicts of Interest Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2019 | Article ID 4194853 | https://doi.org/10.1155/2019/4194853

Risedronate Attenuates Podocyte Injury in Phosphate Transporter-Overexpressing Rats

Yohei Asada,¹Takeshi Takayanagi,¹Tsukasa Kawakami,¹Eisuke Tomatsu,¹Atsushi Masuda,¹Yasumasa Yoshino,¹Sahoko Sekiguchi-Ueda,¹Megumi Shibata,¹Tomihiko Ide,²Hajime Niimi,³Eishin Yaoita,⁴and Yusuke Seino¹ et al.

Academic Editor: Pawel Grzmil

Received27 Jun 2019

Accepted29 Aug 2019

Published23 Oct 2019

Abstract

Osteoporosis patients with chronic kidney disease (CKD) are becoming common in our superaging society. Renal dysfunction causes phosphorus accumulation in the circulating plasma and leads to the development of CKD-mineral bone disorder (MBD). We have previously reported that type III Pi transporter-overexpressing transgenic (Pit-1 TG) rats manifest phosphate (Pi)-dependent podocyte injury. In the present study, we explored the effect of risedronate on Pi-induced podocyte injury in vivo. Pit-1 TG rats and wild-type rats at 5 weeks old were divided into a risedronate-treated group and an untreated group. We subcutaneously administered 5 μg/kg body weight of risedronate or saline twice a week during the experimental period. Risedronate did not alter serum creatinine levels at 5, 8, and 12 weeks of age. However, electron microscopy images showed that thickening of the glomerular basement membrane was improved in the risedronate treatment group. Furthermore, immunostaining for podocyte injury markers revealed that both desmin- and connexin43-positive areas were smaller in the risedronate-treated group than in the untreated group, suggesting that bisphosphonates could rescue Pi-induced podocyte injury. In conclusion, our findings suggest that risedronate could maintain glomerular barrier function by rescuing Pi-induced podocyte injury.

1. Introduction

Phosphate (Pi) is known as an essential component for cell viability via ATP synthesis. On the other hand, Pi overload causes cell stress and induces apoptosis [1]. We have previously shown that high extracellular Pi induces cell death of vascular smooth muscle cells of rat A-10 [2]. Serum Pi level is mainly controlled by three major organs: kidney, bone, and intestine. Among them, reabsorption of Pi in the proximal tubules of the kidney is regulated by parathyroid hormone and other phosphaturic hormones such as fibroblast growth factor-23 [3]. In patients with chronic kidney disease (CKD), CKD-mineral and bone disorder (MBD) develops in association with secondary hyperparathyroidism owing to Pi accumulation and leads to an increased risk of fracture, cardiovascular events, and overall increased mortality [4–6]. Moreover, the Pi load itself contributes to the progression of renal insufficiency and vascular calcification [7–9]. Therefore, the regulation of serum Pi levels in hyperphosphatemia is considered important for improving life expectancy and preventing end-stage renal disease (ESRD).

Nephrotic syndrome, characterized by proteinuria, hypoalbuminemia, and dyslipidemia, occurs mainly because of failure of the glomerular filtration barrier mechanism [10]. The barrier mechanism is constructed of three essential components: the glomerular basement membrane (GBM), podocytes, and glomerular endothelial cells [11]. Among them, the terminally differentiated podocytes play a role as a critical size and charge barrier to prevent proteinuria. Podocyte injury brings on noticeable proteinuria with or without the loss of renal function [12]. Podocytes are injured by underlying diseases of nephrotic syndrome such as membranous nephropathy, minimal-change disease, and diabetic nephropathy [13–15]. We previously reported that transgenic (TG) rats overexpressing the type-III Na-dependent Pi transporter (Pit-1) develop spontaneous cataracts, bone loss, and nephrotic syndrome [16, 17]. In our Pit-1-overexpressing TG rats, their glomeruli showed thickened GBM and podocyte injury, suggesting that Pi overload could damage the glomerular barrier system through podocyte injury [16].

Nephrotic syndrome with persistent proteinuria results in serious complications and progressive kidney disease [10]. Glucocorticoid (GC) is effective in reducing proteinuria and halting the progress of kidney disease in several types of nephrotic syndrome. On the other hand, continuous GC treatment induces adverse side effects such as secondary diabetes and GC-induced osteoporosis (GIOP) [18, 19]. To prevent GIOP, bisphosphonates are currently the first-line drug [19, 20]. Bisphosphonates are very effective in reducing GIOP-associated bone fracture, but their use is restricted in patients with severe kidney dysfunction [21]. Animal experiments have shown that the use of risedronate is associated with increased risk of tubular degeneration and single-cell necrosis in the proximal convoluted tubules [22]. However, the effect of bisphosphonates on glomerulus disease such as nephrotic syndrome without severe kidney dysfunction has not yet been elucidated. In the present study, we examined the diachronic change in renal function in Pit-1 TG rats with risedronate administration to explore the effect of bisphosphonates on glomerular barrier function in vivo.

2. Materials and Methods

2.1. Animals

The mouse Pit-1 gene was ubiquitously expressed under the control of a cytomegalovirus early enhancer element and chicken β-actin (CAG) promoter in TG rats, and upon pronuclear DNA microinjection into rat zygotes [16]. Sodium risedronate hydrate was provided by EA Pharma Co. Ltd. (Tokyo, Japan). Male Pit-1 TG rats and their wild-type littermates (WT) were housed at 24°C with a 12 h/12 h light/dark cycle and were allowed free access to normal rodent chow and water. They were randomly divided into the following four groups: WT rats with risedronate administration (WT-R, n = 13), WT rats without risedronate administration (WT-C, n = 14), Pit-1 TG rats with risedronate administration (TG-R, n = 14), and Pit-1 TG rats without risedronate administration (TG-C, n = 15). Risedronate (5 μg/kg body weight) was subcutaneously administered twice a week from 5 weeks old through 12 weeks old. The dose of risedronate chosen was previously determined as an effective pharmacological dose used in animal experiments by Matheny et al. [23]. The equivalent volume of saline was administered to the control groups without risedronate administration. Blood samples were taken from the tail vein. These samplings were conducted at 5, 8, and 12 weeks of age. Routine serum chemistries were measured using a Hitachi 7180 automatic analyzer (Hitachi High Technologies, Tokyo, Japan). Tissues for histological analysis by light microscopy and electron microscopy were collected at 8 and 12 weeks of age. All animal procedures and a statement of protocol were approved by the Institutional Animal Care and Use committee and government authorities.

2.2. PCR

Genotyping of the transgenic animals was carried out by PCR. Genomic DNA purified from tail clips was digested with proteinase K and hybridized with a specific probe for mouse Pit-1. For subsequent genotyping by PCR, we used the forward primer 5′-ACGGCTTGATAGATGTGG-3’ (681–698 of M73696) and the reverse primer 5′-TAAGGGACTTTCAGACGG-3’ (1234–1217 of M73696). For genotyping, PCR was performed at 95°C for 30 s, 60°C for 30 s (30 cycles), and 72°C for 1 min.

2.3. Light Microscopy

Kidney samples were fixed in 10% neutral-buffered formalin, embedded in paraffin, and cut into sections of 2-μm to 3-μm thickness. The sections were stained with hematoxylin and eosin or periodic acid-Schiff (PAS). Using light microscopy at low power magnification, a plan of suitable sections was drawn with the position of every glomerulus marked, which generally covered the whole section. At high power magnification, glomeruli were examined for lesions.

2.4. Electron Microscopy

Small pieces of tissue, 2 × 4 mm, were fixed in 2.5% glutaraldehyde (GA)/0.05 M sodium phosphate, at pH 7.4 (PB), for 2 h. After washing with PB, samples were dehydrated in a graded ethanol series and treated with n-butyl glycidyl ether before being embedded in Epon 812 (Taab Laboratories, Aldermaston, UK). Ultrathin sections (0.1 μm) were doubly stained with 2% uranyl acetate and 1% lead citrate and then observed using a JEM-1010 (JEOL, Tokyo, Japan) transmission electron microscope (TEM) at an accelerating voltage of 80 kV. The TEM images were analyzed using image-J, and the width of the GBM was measured between the cytoplasmic membranes right under the foot processes and the glomerular endothelial cells. The intervals of measurement were 1 micrometer along the longitudinal axis of glomerular basement membranes.

2.5. Immunofluorescence Microscopy

The indirect immunofluorescence technique was applied to frozen kidney sections and outgrowths from glomeruli as described previously [24]. In brief, the rat kidneys were snap-frozen at −70°C, sectioned at a thickness of 3 μm in a cryostat, and fixed in 2% paraformaldehyde in phosphate-buffered saline (PBS) for 5 min. The primary antibodies used were as follows: monoclonal anti-nephrin antibody (5-1-6; courtesy of Dr. H. Kawachi, Niigata University, Niigta, Japan) [25]; murine monoclonal anti-desmin antibody (clone D-33; Dako Cytomation, Glostrup, Denmark); rabbit anti-connexin43 antibody (Sigma-Aldrich, St Louis, MO, USA); murine monoclonal anti-ZO-1 antibody (Zymed Laboratories, South San Francisco, CA, USA); and rabbit anti-laminin antibody (Dako Cytomation). For double-label immunofluorescence microscopy, monoclonal anti-nephrin antibody and rabbit anti-laminin antibody, murine monoclonal anti-desmin antibody and rabbit anti-laminin antibody, and rabbit anti-connexin43 antibody and murine monoclonal anti-ZO-1 antibody were mixed and applied simultaneously as primary antibodies. After washing with PBS, the sections were stained with fluorescein isothiocyanate (FITC)- or tetramethyl rhodamine isothiocyanate (TRITC)-conjugated anti-rabbit IgG, rewashed with PBS and subsequently reacted with FITC- or Texas Red-conjugated anti-mouse IgG. PBS, normal rabbit serum, or murine IgG monoclonal antibody (against rotavirus), shown not to react with rat glomeruli, were used as negative controls for the primary antibodies. 4′,6-diamidino-2-phenylindole and dihydrochloride (Dojindo, Kumamoto, Japan) were used for nuclear staining. Immunofluorescence of the sections was observed using a laser-scanning confocal microscope (A1Rsi; Nikon, Tokyo, Japan).

2.6. Statistical Analysis

Results are expressed as means ± SD. Data were analyzed using JMP ver.13.0. Statistical analyses were performed by ANOVA and Tukey HSD tests. The level of significance was set at .

3. Results

Risedronate did not affect serum creatinine levels of both WT and TG rats (Table 1). Serum calcium levels in the TG-R group were lower than in the WT-R group at 5 weeks, but reached the same level as other groups at 8 and 12 weeks of age. Serum phosphorus and creatinine levels among all four groups were identical.

Histological examination of kidney sections with PAS staining at 8 and 12 weeks of age showed hyaline and vacuolar degeneration which were conspicuously observed in both TG groups but not in control groups (Figure 1). Hyaline droplet-positive lesions were observed in almost half of glomeruli. Tubular atrophy and interstitial cell infiltration were infrequent. Ultrastructural analysis by TEM showed podocyte effacement and thickness of GBM in the kidney of 12-week-old TG-C rats (Figure 2). In addition, TG-C rats had lost the three-layered structure of the GBM at 12 weeks of age. When risedronate was administered to TG rats (TG-R), podocyte effacement was rescued, and the GBM in TG-R rats retained its three-layered structure (Figure 2). The width of the GBM in TG-R rats was significantly narrower than that in TG-C rats (Figure 3).

By immunofluorescence microscopy, we examined podocyte constituent proteins (nephrin) and podocyte injury markers (desmin and connexin43) at the age of 12 weeks. The localization and staining intensity of nephrin were the same among all four groups (Figure 4). In contrast, immunostaining for podocyte injury markers showed remarkable differences between the TG groups. The TG-C group showed wider and clearer desmin-enhanced areas than the WT groups. In the TG-R group, the area was obviously narrower and weaker than in the TG-C group (Figure 5). Connexin43-enhanced areas were observed as a dotted pattern along the glomerular capillary wall in the TG-C group, while in the TG-R group, the area exhibited fewer dots with connexin43 staining than the TG-C group (Figure 6).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

Figure 4

Immunofluorescence microscopy for nephrin (green) in glomeruli of WT-C (a and e), WT-R (b and f), TG-C (c and g), and TG-R rats (d and h) at 12 weeks of age. Double-labeled immunostaining for laminin (red) was carried out to locate the glomerular capillary wall. Experimental groups were as follows: wild-type littermates (WT) without risedronate administration (WT-C), WT rats with risedronate administration (WT-R), Pit-1 TG rats with risedronate administration (TG-R), and Pit-1 TG rats without risedronate administration (TG-C). Bar = 50 μm (a, b, c, and d). Bar = 25 μm (e, f, g, and h).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

Figure 5

Immunofluorescence microscopy for desmin (green) in glomeruli of WT-C (a and e), WT-R (b and f), TG-C (c and g), and TG-R rats (d and h) at 12 weeks of age. Double-labeled immunostaining for laminin (red) was carried out to locate the glomerular capillary wall. Experimental groups were as follows: wild-type littermates (WT) without risedronate administration (WT-C), WT rats with risedronate administration (WT-R), Pit-1 TG rats with risedronate administration (TG-R), and Pit-1 TG rats without risedronate administration (TG-C). Bar = 50 μm (a, b, c, and d). Bar = 25 μm (e, f, g, and h).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

Figure 6

Immunofluorescence microscopy for connexin43 (green) in glomeruli of WT-C (a and e), WT-R (b and f), TG-C (c and g), and TG-R rats (d and h) at 12 weeks of age. Double-labeled immunostaining for tight junction protein ZO-1 (red in E-H) was carried out to locate the glomerular capillary wall. Experimental groups were as follows: wild-type littermates (WT) without risedronate administration (WT-C), WT rats with risedronate administration (WT-R), Pit-1 TG rats with risedronate administration (TG-R), and Pit-1 TG rats without risedronate administration (TG-C). Bar = 50 μm (a, b, c, and d). Bar = 25 μm (e, f, g, and h).

4. Discussion

In the present study, we found that risedronate administration could save the barrier mechanisms of the glomerulus in Pit-1 TG rats. Although bisphosphonates, including risedronate, are contraindicated for severe renal insufficiency, our study showed that they exert a protective effect on glomeruli in the kidney affected by Pi overload.

Nephrotic syndrome is characterized by massive proteinuria with damaged barrier function of the glomerulus [26]. Pathological proteinuria is associated with both effacement of foot processes and the loss of slit diaphragms [27, 28]. Podocytes cover the GBM, and their interdigitated foot processes interlink with slit diaphragms. Both the GBM and the slit diaphragms are essential components of the glomerular filtration barrier, which prevents protein loss into the urine. The GBM is the central, noncellular layer of the glomerular filtration barrier that is situated between the two cellular components: the fenestrated endothelial cells and the interdigitated podocyte foot processes. The GBM is synthesized and repaired by podocytes postnatally, and GBM abnormality could indicate podocyte dysfunction [29, 30]. We have shown that risedronate administration improves thickening of the GBM and maintains its three-layered structure in Pit-1 TG rats. In addition, risedronate attenuates the expression of podocyte injury markers such as desmin and connexin43 in Pit-1 TG rats. These results suggest that risedronate rescues glomerular barrier function by protecting against Pi-induced podocyte injury. Bisphosphonates including risedronate are currently the most important class of antiresorptive agents used in the treatment of metabolic bone diseases including primary and secondary osteoporosis, tumor-associated osteolysis, and hypercalcemia [31]. Nephrotic syndrome is often treated with GC, and GIOP and subsequent fractures are a significant concern in these patients [19, 20]. Bisphosphonates are effective in treating GIOP and are considered as the first-line drug to prevent fracture due to GIOP [19, 20]. Theoretically, bisphosphonates should be administered to nephrotic syndrome patients with GIOP, but all bisphosphonates carry warning labels or contraindications against use in patients with severe renal dysfunction [21]. A histopathological study revealed that the proximal convoluted tubules are the primary target for renal injury caused by bisphosphonates, and tubular degeneration and single-cell necrosis of these tubules were observed with bisphosphonate administration in a rat experimental model [22]. However, the effect of bisphosphonates on the glomerulus and its barrier function has not yet been elucidated. In this study, we show that the serum creatinine level was not elevated with risedronate administration. Moreover, no renal tubule necrosis was observed. In fact, risedronate improved Pi-induced damage to the barrier mechanism in Pit-1 TG rats. These results suggest that risedronate could be safe and show a rather beneficial effect on nephrotic syndrome without ESRD.

Inorganic phosphate (Pi) is a key element of skeletal mineralization and an essential nutrient for the maintenance of cell viability through the process of energy metabolism, producing ATP [32]. The ubiquitous expression of Pit-1 is compatible with housekeeping maintenance of intracellular Pi homeostasis by transporting Pi from interstitial fluid for normal cellular functions [33]. Pit-1 knockout mice, generated by homologous recombination in embryonic stem cells, died around midgestation [34]. Thus, Pit-1 seems to play an essential role in cell survival and tissue development. In contrast, accumulating evidence suggests that continuous Pi overload of nonskeletal tissues from the extracellular milieu causes cell stress [1]. In the clinical setting, high plasma Pi is an independent risk factor for an accelerated decline in renal function and higher mortality in predialysis patients [8]. Maintenance of Pi within the normal range is one of the crucial factors in preventing renal failure in CKD patients. Nowadays, CKD-MBD is a critical concept in achieving better prognosis in the superaging population because renal function decreases with aging. In the aging population, comorbidities with CKD and osteoporosis are more common than in the younger generation [35], and the number of bisphosphonate users with CKD is increasing. Therefore, our results showing a beneficial effect of bisphosphonate on glomerular barrier function might contribute to better prognosis of CKD-MBD patients without ESRD. Thus, the use of bisphosphonates in osteoporosis patients with moderate CKD may not only prevent osteoporotic fractures but also protect glomerular function rather than impair renal function.

There are three possible renoprotective mechanisms of bisphosphonate in this study:

4.1. Inhibition of Direct Pi Uptake by Glomerular Epithelial Cells

Bisphosphonates are in a nonpolar lipophilic configuration under the acidic environment of the resorption pit beneath the ruffled borders of osteoclasts, and they transverse the cytoplasmic membrane of the osteoclast specifically [36]. In a neutral environment, they assume a polar hydrophilic configuration, and they use transporters to cross the cytoplasmic membrane of nonosteoclastic cells. Bisphosphonates are considered to enter into soft-tissue cells via SLC20 and/or SLC34 Pi transporters [37]. Therefore, bisphosphonates could compete with Pi by passing from the extracellular fluid into the cytoplasm through Pit-1 and rescue podocytes from Pi stress.

4.2. Suppression of Bone Resorption by Bisphosphonate Could Reduce the Outflow of Pi into the Blood, Resulting in Relief of the Pi Burden on the Kidney

Ibandronate treatment did not significantly affect the increase in serum levels of Pi, creatinine, blood urea nitrogen, or PTH in uremic rats. However, their artery calcification was prevented, and this correlated with decreasing serum bone Gla protein (BGP; osteocalcin), a marker of an increased bone turnover [38]. Therefore, unchanged Pi concentration in the present study cannot preclude an indirect effect of bisphosphonate on podocytes.

4.3. Inhibition of Activation of the Rho-Rho Kinase-Dependent Pathway by Inhibition of Farnesyl Pyrophosphate Synthase (FPPS)

FPPS is known to be expressed in kidney cells, where it activates small GTPases including Rho kinase [39]. Rho kinase is an effector molecule of Rho A, and Rho A plays an important role in maintaining the integrity of the glomerular filtration barrier under basal conditions. However, enhancement of Rho A activity above basal levels promotes podocyte injury [40]. Activation of Rho A in podocytes leads to albuminuria accompanied by a range of histologic changes characteristic of minimal-change disease and focal segmental glomerulosclerosis in humans. Although most changes are reversible, severe and prolonged activation of Rho A may cause irreversible glomerulosclerosis [41]. Accumulating evidence shows that activation of Rho kinase impairs podocyte function. Podocyte injury in the progression of diabetic nephropathy could also be mediated by activation of Rho kinase [42]. Nitrogen-containing bisphosphonates including risedronate could inhibit FPPS, thus leading to inhibition of Rho kinase. Therefore, bisphosphonates might exert a cytoprotective effect on podocytes through inhibition of the Rho-Rho kinase pathway in podocytes.

We have previously shown that Pi uptake of primary cultured podocytes from Pit-1 TG rats is higher than WT rats [16], and we found that urinary Pi excretion was elevated in Pit-1 TG rats regardless of risedronate treatment (data not shown). Therefore, higher urinary Pi excretion in TG rats could be burden on podocytes in Pit-1 TG rats, and it is likely that risedronate protects podocytes from Pi stress by not systemic but local mechanisms. To explore precise mechanisms of risedronate on Pi-induced podocyte injury, further examination such as by molecular biology technique would be required.

5. Conclusion

Our findings suggest that risedronate can maintain the glomerular barrier function by rescuing phosphate-induced podocyte injury.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

There are no conflicts of interest regarding the publication of this paper.

Acknowledgments

We would like to thank Ms Sayaka Nomura and Ms Shihomi Sakai for their technical assistance. This study was supported by the contribution from EA Pharma Co., Ltd.

References

Z. T. Schafer and S. Kornbluth, “The apoptosome: physiological, developmental, and pathological modes of regulation,” Developmental Cell, vol. 10, no. 5, pp. 549–561, 2006.
View at: Publisher Site | Google Scholar
K. Nishiwaki-Yasuda, A. Suzuki, A. Kakita et al., “Vasopressin stimulates Na-dependent phosphate transport and calcification in rat aortic smooth muscle cells,” Endocrine Journal, vol. 54, no. 1, pp. 103–112, 2007.
View at: Publisher Site | Google Scholar
S. Fukumoto, “Phosphate metabolism and vitamin D,” BoneKEy Reports, vol. 3, pp. 1–5, 2014.
View at: Publisher Site | Google Scholar
T. Isakova, T. L. Nickolas, M. Denburg et al., “KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD),” American Journal of Kidney Diseases, vol. 70, no. 6, pp. 737–751, 2017.
View at: Publisher Site | Google Scholar
N. X. Chen and S. M. Moe, “Pathophysiology of vascular calcification,” Current Osteoporosis Reports, vol. 13, no. 6, pp. 372–380, 2015.
View at: Publisher Site | Google Scholar
S. Jono, M. D. McKee, C. E. Murry et al., “Phosphate regulation of vascular smooth muscle cell calcification,” Circulation Research, vol. 87, no. 7, pp. E10–E17, 2000.
View at: Publisher Site | Google Scholar
A. Levin, O. Djurdjev, M. Beaulieu, and L. Er, “Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort,” American Journal of Kidney Diseases, vol. 52, no. 4, pp. 661–671, 2008.
View at: Publisher Site | Google Scholar
N. Voormolen, M. Noordzij, D. C. Grootendorst et al., “High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients,” Nephrology Dialysis Transplantation, vol. 22, no. 10, pp. 2909–2916, 2007.
View at: Publisher Site | Google Scholar
N. Nagano, S. Miyata, S. Obana et al., “Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency,” Nephrology Dialysis Transplantation, vol. 18, no. 10, pp. 2014–2023, 2003.
View at: Publisher Site | Google Scholar
C. Kodner, “Diagnosis and management of nephrotic syndrome in adults,” American Family Physician, vol. 93, no. 6, pp. 479–485, 2016.
View at: Google Scholar
B. Haraldsson, J. Nyström, and W. M. Deen, “Properties of the glomerular barrier and mechanisms of proteinuria,” Physiological Reviews, vol. 88, no. 2, pp. 451–487, 2008.
View at: Publisher Site | Google Scholar
S. J. Shankland, “The podocyte’s response to injury: role in proteinuria and glomerulosclerosis,” Kidney International, vol. 69, no. 12, pp. 2131–2147, 2006.
View at: Publisher Site | Google Scholar
L. Kaufman, G. Yang, H. Kayo et al., “The homophilic adhesion molecule sidekick-1 contributes to augmented podocyte aggregation in HIV-associated nephropathy,” The FASEB Journal, vol. 21, no. 7, pp. 1367–1375, 2007.
View at: Publisher Site | Google Scholar
D. Kerjaschki and T. J. Neale, “Molecular mechanisms of glomerular injury in rat, experimental membranous nephropathy (Heymann nephritis),” Journal of the American Society of Nephrology, vol. 7, no. 12, pp. 2518–2526, 1996.
View at: Google Scholar
M. E. Pagtalunan, P. L. Miller, S. Jumping-Eagle et al., “Podocyte loss and progressive glomerular injury in type II diabetes,” Journal of Clinical Investigation, vol. 99, no. 2, pp. 342–348, 1997.
View at: Publisher Site | Google Scholar
S. Sekiguchi, A. Suzuki, S. Asano et al., “Phosphate overload induces podocyte injury via type III Na-dependent phosphate transporter,” American Journal of Physiology-Renal Physiology, vol. 300, no. 4, pp. F848–F856, 2011.
View at: Publisher Site | Google Scholar
A. Suzuki, P. Ammann, K. Nishiwaki-Yasuda et al., “Effects of transgenic pit-1 overexpression on calcium phosphate and bone metabolism,” Journal of Bone and Mineral Metabolism, vol. 28, no. 2, pp. 139–148, 2010.
View at: Publisher Site | Google Scholar
S. Suh and M. K. Park, “Glucocorticoid-induced diabetes mellitus: an important but overlooked problem,” Endocrinology and Metabolism, vol. 32, no. 2, p. 180, 2017.
View at: Publisher Site | Google Scholar
L. Buckley, G. Guyatt, H. A. Fink et al., “2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis,” Arthritis & Rheumatology, vol. 69, no. 8, pp. 1521–1537, 2017.
View at: Publisher Site | Google Scholar
Y. Suzuki, H. Nawata, S. Soen, S. Fujiwara, and H. Nakayama, “Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research : 2014 update,” Journal of Bone and Mineral Metabolism, vol. 32, no. 4, pp. 337–350, 2014.
View at: Publisher Site | Google Scholar
S. L. West, P. Patel, and S. A. Jamal, “How to predict and treat increased fracture risk in chronic kidney disease,” Journal of Internal Medicine, vol. 278, no. 1, pp. 19–28, 2015.
View at: Publisher Site | Google Scholar
T. Pfister, E. Atzpodien, B. Bohrmann, and F. Bauss, “Acute renal effects of intravenous bisphosphonates in the rat,” Basic Clinical Pharmacology Toxicology, vol. 97, no. 6, pp. 374–381, 2005.
View at: Publisher Site | Google Scholar
J. B. Matheny, C. R. Slyfield, E. V. Tkachenko et al., “Anti-resorptive agents reduce the size of resorption cavities: a three-dimensional dynamic bone histomorphometry study,” Bone, vol. 57, no. 1, pp. 233–245, 2013.
View at: Publisher Site | Google Scholar
E. Yaoita, J. Yao, Y. Yoshida et al., “Up-regulation of Connexin43 in glomerular podocytes in response to injury,” The American Journal of Pathology, vol. 161, no. 5, pp. 1597–1606, 2002.
View at: Publisher Site | Google Scholar
P. S. Topham, H. Kawachi, S. A Haydar et al., “Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin,” Journal of Clinical Investigation, vol. 104, no. 11, pp. 1559–1566, 1999.
View at: Publisher Site | Google Scholar
W. Y. Ding and M. A. Saleem, “Current concepts of the podocyte in nephrotic syndrome,” Kidney Research and Clinical Practice, vol. 31, no. 2, pp. 87–93, 2012.
View at: Publisher Site | Google Scholar
K. Asanuma and P. Mundel, “The role of podocytes in glomerular pathobiology,” Clinical and Experimental Nephrology, vol. 7, no. 4, pp. 255–259, 2003.
View at: Publisher Site | Google Scholar
J. Oh, J. Reiser, and P. Mundel, “Dynamic (re)organization of the podocyte actin cytoskeleton in the nephrotic syndrome,” Pediatric Nephrology, vol. 19, no. 2, pp. 130–137, 2004.
View at: Publisher Site | Google Scholar
J. Ashley Jefferson, C. E. Alpers, and S. J. Shankland, “Podocyte biology for the bedside,” Am J Kidney Dis, vol. 58, no. 5, pp. 835–845, 2011.
View at: Publisher Site | Google Scholar
J. H. Suh and J. H. Miner, “The glomerular basement membrane as a barrier to albumin,” Nature Reviews Nephrology, vol. 9, no. 8, pp. 470–477, 2013.
View at: Publisher Site | Google Scholar
M. T. Drake, B. L. Clarke, and M. Sundeep Khosla, “Bisphosphonates: mechanism of action and role in cliical practice,” Mayo Clinic Proceedings, vol. 83, no. 9, pp. 1032–1045, 2008.
View at: Publisher Site | Google Scholar
E. Takeda, Y. Taketani, K Morita et al., “Molecular mechanisms of mammalian inorganic phosphate homeostasis,” Advances in Enzyme Regulation, vol. 40, no. 1, pp. 285–302, 2000.
View at: Publisher Site | Google Scholar
M. Inden, M. Iriyama, M. Zennami et al., “The type III transporters (PiT-1 and PiT-2) are the major sodium-dependent phosphate transporters in the mice and human brains,” Brain Research, vol. 1637, pp. 128–136, 2016.
View at: Publisher Site | Google Scholar
M. H. Festing, M. Y. Speer, H. Y. Yang, and C. M. Giachelli, “Generation of mouse conditional and null alleles of the type III sodium-dependent phosphate cotransporter PiT-1,” Genesis, vol. 47, pp. 858–863, 2009.
View at: Publisher Site | Google Scholar
K. Nitta, A. Yajima, and K. Tsuchiya, “Management of osteoporosis in chronic kidney disease,” Internal Medicine, vol. 56, no. 24, pp. 3271–3276, 2017.
View at: Publisher Site | Google Scholar
A. J. Roelofs, K. Thompson, S. Gordon, and M. J. Rogers, “Molecular mechanisms of action of bisphosphonates: current status,” Clinical Cancer Research, vol. 12, no. 20, pp. 6222–6231, 2006.
View at: Publisher Site | Google Scholar
K. Shima, M. Tsuchiya, T. Oizumi, T. Takano-Yamamoto, S. Sugawara, and Y. Endo, “Inflammatory effects of nitrogen-containing bisphosphonates (N-BPs): modulation by non-N-BPs,” Biological & Pharmaceutical Bulletin, vol. 40, no. 1, pp. 25–33, 2017.
View at: Publisher Site | Google Scholar
P. A. Price, A. M. Roublick, and M. K. Williamson, “Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate,” Kidney International, vol. 70, no. 9, pp. 1577–1583, 2006.
View at: Publisher Site | Google Scholar
S. Krisans, “Cell compartmentalization of cholesterol biosynthesis,” Annals of the New York Academy of Sciences, vol. 804, no. 1, pp. 142–163, 1966.
View at: Publisher Site | Google Scholar
L. Wang, M. J. Ellis, J. A. Gomez et al., “Mechanisms of the proteinuria induced by Rho GTPases,” Kidney International, vol. 81, no. 11, pp. 1075–1085, 2012.
View at: Publisher Site | Google Scholar
L. Zhu, R. Jiang, N. Jones, T. Takano, and L. Aoudjit, “Activation of RhoA in podocytes induces focal segmental glomerulosclerosis,” Journal of the American Society of Nephrology, vol. 22, no. 9, pp. 1621–1630, 2011.
View at: Publisher Site | Google Scholar
M. Keiichiro, D. Kawanami, O. Rina et al., “Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1α,” Kidney International, vol. 84, no. 3, pp. 545–554, 2013.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2019 Yohei Asada et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies